Updates at market open, adds further analyst comment in 4-5 bullets
** Shares in Novo Nordisk NOVOb.CO rise 3% after the Danish drugmaker posted a quarterly operating profit above estimates
** Novo books EBIT of 38.79 billion Danish crowns ($5.91 billion) for Q1, 4% above consensus expectations
** It now expects its sales in 2025 to grow 13%-21%, against the 16%-24% growth it saw in in February
** J.P.Morgan says the outlook cut was largely anticipated by the market
** Any weakness today is a buying opportunity ahead of the potential for improving Wegovy growth, JPM says
** Jefferies analysts say the outlook cut is likely around 1-2 pp more than expected
** Stock down around 29% YTD as of Tuesday's close
($1 = 6.5648 Danish crowns)
(Reporting by Boleslaw Lasocki)
((boleslaw.lasocki@thomsonreuters.com; +48 58 769 66 00;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.